Shaping the Future of MDS Management: Expert Forecasts
By Thomas LeBlanc, MD, MA, Jamie Koprivnikar, MD, Andrew Brunner, MD - Last Updated: February 18, 2025Thomas LeBlanc, MD, MA, of Duke Cancer Institute, Jamie Koprivnikar, MD, of Hackensack University Medical Center, and Andrew Brunner, MD, of Massachusetts General Hospital, give their predictions for the future of MDS management and highlight the directions of clinical research they find most exciting.
Advertisement
Advertisement
Related Posts
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.